Home
OverviewAbout10 LeapsCollaborationImpact
OverviewLeaps TalksChapter FilmsLeaps.orgPartners
AgricultureHealth
OverviewAnnual ReviewBreakthrough StudyPress ReleasesIn the NewsReportsLeaps LeadershipPress KitMedia Contact
Team
  • Approach
    • Overview
    • About
    • 10 Leaps
    • Collaboration
    • Impact
  • Engagement
    • Overview
    • Leaps Talks
    • Chapter Films
    • Leaps.org
    • Partners
    • Agriculture
    • Health
  • News
    • Overview
    • Annual Review
    • Breakthrough Study
    • Press Releases
    • In the News
    • Reports
    • Leaps Leadership
    • Press Kit
    • Media Contact
  • Team
ContactImprintPrivacy StatementConditions of Use
sign up for our newsletter
see more companies

Soufflé Therapeutics

logo

Vision

Potent, precise and safe medicines can be designed and developed for all diseases.

Approach

Soufflé discovers and develops cell-selective ligands to deliver siRNA-based medicines which are engineered, specific and transferred across the cell membrane to their target. Soufflé combines proprietary technologies for identification of cell-selective receptors, ligand optimization and potent siRNA engineering to create and commercialize safer, stronger, and more durable medicines that will help improve patient lives.

Soufflé Therapeutics is addressing

  • Leap 01 / Cure genetic diseases
  • Leap 02 / Provide sustainable organ and tissue replacement
  • Leap 04 / Prevent and cure cancer
  • Leap 05 / Protect brain and mind
  • Leap 06 / Reverse autoimmune diseases and chronic inflammation

CEO:

Amir Nashat ScD

Founders:

Professor Robert Langer ScD

Professor Daniel G. Anderson PhD

Professor Victor Kotelianski ScD

Professor Brad Pentelute PhD

First investment:

October 2022

www.souffletx.com